<DOC>
	<DOCNO>NCT00422019</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety AMG 102 patient Advanced Renal Cancer .</brief_summary>
	<brief_title>A Phase II Study Treat Subjects With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Dihydrotachysterol</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>document histologically confirm advanced metastatic renal cell carcinoma primary tumor place follow nephrectomy measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique ( CT MRI ) ≥ 10 mm spiral CT scan 3 relapse ( prior systemic treatment ) unable receive fail prior therapy vascular endothelial growth factor ( VEGF ) bind agent VEGF receptor tyrosine kinase inhibitor multikinase inhibitor tissue block tissue section initial upon diagnosis advance metastatic disease available submission central laboratory within approximately 4 week enrollment approval grant sponsor ( upon receipt justification sample available ) age ≥ 18 year ECOG performance status 02 hemoglobin concentration ≥ 9 g/dL absolute neutrophil count ≥ 1.5 x 10 ( 9th ) /L correct serum calcium ≤ 10 mg/dL either serum creatinine &lt; 2.0 x upper limit normal OR creatinine clearance &gt; 40 mL/min alanine aminotransferase ≤ 2.5 time upper limit normal &lt; 5.0 x ULN subject document liver metastasis primary hepatic neoplasm serum total bilirubin ≤ 2.5 time upper limit normal studyspecific procedure , appropriate write informed consent must obtain active brain metastasis ; brain metastasis allow provide treated surgery and/or radiation therapy show evidence progression cerebral CT MRI scan 2 month follow surgery and/or radiation therapy concurrent severe and/or uncontrolled medical disease ( e.g. , uncontrolled diabetes , congestive cardiac failure , myocardial infarction within 6 month enrollment ) could compromise participation study document history human immunodeficiency virus infection document history viral chronic hepatitis receive biologic , small molecule , immunotherapy , chemotherapy , radiotherapy agent treat renal cancer within 28 day enrollment treat previously cMet HGF target therapy concurrent prior ( within 7 day enrollment ) anticoagulation therapy , except : Use lowdose warfarin ( &lt; 2 mg/day ) prophylaxis central venous catheter thrombosis Use low molecular weight heparin ( LMWH , e.g. , enoxaparin sodium [ Lovenox ] unfractionated heparin prophylaxis central venous catheter thrombosis allow concurrent use hormone chemotherapeutic agent except steroid give adrenal failure hormone administer nondiseaserelated condition ( eg , insulin diabetes ) ; except noncancer reason concurrent palliative therapeutic radiation therapy currently enrol yet complete least 30 day since end investigational device therapy , subject receive investigational agent ( ) active infection require treatment within 1 week enrollment undergone major surgery within 4 week enrollment recover prior surgery past current history another neoplasm , except curatively treat nonmelanoma skin cancer , carcinoma situ cervix primary solid cancer know active disease present curative treatment administer last 3 year know allergy sensitivity excipients investigational product administer pregnant breast feed consent use adequate contraceptive precaution course study 6 month last administration investigational product : female subject postmenopausal ( menstrual period minimum 12 month study entry ) document surgically sterile bound exclusion previously treat AMG 102 previously enrol study available followup assessment disorder compromise ability subject give write informed consent and/or comply study procedure unable begin protocol specify treatment within 3 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Renal Cancer</keyword>
	<keyword>Kidney Cancer</keyword>
</DOC>